Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings

American Journal of Psychiatry

Volumn 155, Issue 11, 1998, Pages 1490-1501

  Dalack, Gregory W ^a   Healy, Daniel J ^b   Meador Woodruff, James H ^b  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BUNGAROTOXIN; BUNGAROTOXIN; DOPAMINE; GLUTAMIC ACID; NICOTINE; NICOTINIC RECEPTOR;

ARTICLE; DISEASE ASSOCIATION; HUMAN; MOTOR DYSFUNCTION; NEUROCHEMISTRY; NEUROMODULATION; NEUROTRANSMISSION; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING;

EID: 0031786335     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.11.1490     Document Type: Article

References (100)

1. Masterson E, O'Shea B: Smoking and malignancy in schizophrenia. Br J Psychiatry 1984; 145:429-432
2. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA: Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143:993-997
3. Goff DC, Henderson DC, Amico E: Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149:1189-1194
4. Ziedonis DM, Kosten TR, Glazer WM, Frances RJ: Nicotine dependence and schizophrenia. Hosp Community Psychiatry 1994; 45:204-206
5. Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW: Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders. Schizophr Res 1998; 33:113-118
6. Reducing the Health Consequences of Smoking: 25 Years of Progress - a Report of the Surgeon General: DHHS publication CDC-89-8411. Rockville, Md, US Department of Health and Human Services, Public Health Service, Centers for Disease Control, 1989
7. Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli SK, Fleiss J, Cooper TB: Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clin Pharmacol Ther 1993; 54:670-679
8. Covey L, Hughes DC, Glassman AH, Blazer DG, George LK: Ever-smoking, quitting, and psychiatric disorders: evidence from the Durham, North Carolina, Epidemiologic Catchment Area. Tobacco Control 1994; 3:222-227
9. Eastwood R: Weeding out (letter). Lancet 1993; 341:1316
10. Addington J, el-Guebaly N, Addington D, Hodgins D: Readiness to stop smoking in schizophrenia. Can J Psychiatry 1997; 42:49-52
11. Ziedonis DM, George TP: Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997; 23:247-254
12. Cigarette smoking-attributable mortality and years of potential life lost - United States, 1990. MMWR Morb Mortal Wkly Rep 1993; 42:645-649
13. Tsuang MT, Woolson RF, Fleming JA: Premature deaths in schizophrenia and affective disorders: an analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry 1980; 37:979-983
14. Allebeck P, Wistedt B: Mortality in schizophrenia. Arch Gen Psychiatry 1986; 43:650-653
15. Buda M, Tsuang MT, Fleming JA: Causes of death in DSM-III schizophrenics and other psychotics (atypical group). Arch Gen Psychiatry 1988; 45:283-285
16. Mortensen PB, Juel K: Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand 1990; 81:372-377
17. Tabbane K, Joober R, Spadone C, Poirier MF, Olié JP: Mortalité et causes de décès dans la schizophrénie: revue de la littérature. L'Encéphale 1993; 19:23-28
18. Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L: Cigarette smoking is associated with abnormal involuntary movements in the general male population - a study of men born in 1933. Biol Psychiatry 1997; 41:717-723
19. Youssef HA, Waddington JL: Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia. Acta Psychiatr Scand 1987; 75:74-77
20. O'Farrell TJ, Connors GJ, Upper D: Addictive behaviors among hospitalized psychiatric patients. Addict Behav 1983; 18:329-333
21. Gopalaswamy AK, Morgan R: Smoking in chronic schizophrenia (letter). Br J Psychiatry 1986; 149:523
22. Cigarette smoking among adults - United States, 1991. MMWR Morb Mortal Wkly Rep 1993; 42:230-233
23. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM: Schizophrenia and smoking: an epidemiological survey in a state hospital. Am J Psychiatry 1995; 152:453-455
24. Sandyk R, Kay SR: Tobacco addiction as a marker of age of onset of schizophrenia. Int J Neurosci 1991; 57:259-262
25. Glynn SM, Sussman S: Why patients smoke (letter). Hosp Community Psychiatry 1990; 41:1027-1028
26. Olincy A, Young DA, Freedman R: Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry 1997; 42:1-5
27. Dalack GW, Becks L, Pomerleau C, Meador-Woodruff JH: Cigarette smoking and psychiatric illness: an outpatient survey in a VA mental health clinic (abstract). Addiction 1997; 92: 624
28. Hall RG, Duhamel M, McClanahan R, Miles G, Nason C, Rosen S, Schiller P, Tao-Yonenaga L, Hall SM: Level of functioning severity of illness, and smoking status among chronic psychiatric patients. J Nerv Ment Dis 1995; 183:468-471
29. Sandyk R: Cigarette smoking: effects on cognitive functions and drug-induced parkinsonism in chronic schizophrenia. Int J Neurosci 1993; 70:193-197
30. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812
31. Dalack GW, Meador-Woodruff JH: Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature. Schizophr Res 1996; 22:133-141
32. Hamera E, Schneider JK, Deviney S: Alcohol, cannabis, nicotine and caffeine use and symptom distress in schizophrenia. J Nerv Ment Dis 1995; 183:559-565
33. Morens DM, Grandinetti A, Reed D, White LR, Ross GW: Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology 1995; 45:1041-1045
34. Decina P, Caracci G, Sandik R, Berman W, Mukherjee S, Scapicchio P: Cigarette smoking and neuroleptic-induced parkinsonism. Biol Psychiatry 1990; 28:502-508
35. Menza MA, Grossman N, Van Horn M, Cody R, Forman N: Smoking and movement disorders in psychiatric patients. Biol Psychiatry 1991; 30:109-115
36. Yassa R, Lal S, Korpassy A, Ally J: Nicotine exposure and tardive dyskinesia. Biol Psychiatry 1987; 22:67-72
37. Munetz MR, Benjamin S: How to examine patients using the Abnormal Involuntary Movement Scale. Hosp Community Psychiatry 1988; 39:1172-1177
38. Wirshing WC, Engle J, Levin E, Cummings JL, Rose J: The acute effects of smoking on tardive dyskinesia, in 1989 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1989, p 89
39. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R: Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992; 32:607-616
40. Adler LE, Hoffer LD, Wiser A, Freedman R: Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993; 150:1856-1861
41. Levin ED, Wilson W, Rose JE, McEvoy J: Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology 1996; 15:429-436
42. Olincy A, Ross RG, Young DA, Roath M, Freedman R: Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology 1998; 18:175-185
43. Waldo MC, Carey G, Myles-Worsley M, Cawthra E, Adler LE, Nagamoto HT, Wender P, Byerley W, Plaetke R, Freedman R: Codistribution of a sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res 1991; 39:257-268
44. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W: Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997; 94:587-592
45. Levin ED: Nicotinic systems and cognitive function. Psychopharmacology (Berl) 1992; 108:417-431
46. Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR: Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985; 20:329-332
47. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM: Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl) 1986; 90:468-470
48. George TP, Sernyak MJ, Ziedonis DM, Woods SW: Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56:344-346
49. Dawe S, Gerada C, Russell MAH, Gray JA: Nicotine intake in smokers increases following a single dose of haloperidol. Psychopharmacology (Berl) 1995; 117:110-115
50. McEvoy JP, Freudenreich O, Levin ED, Rose JE: Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 1995; 119:124-126
51. McEvoy J, Freudenreich O, McGee M, VanderZwaag C, Levin E, Rose J: Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995; 37:550-552
52. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R: Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 1996; 40:181-188
53. Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486
54. Carlsson M, Carlsson A: Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13:272-276
55. Carlsson M, Carlsson A: Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 1990; 16: 425-432
56. Meltzer HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989; 99:S18-S27
57. Joyce JN, Meador-Woodruff JH: Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology 1997; 16:375-384
58. Hollmann M, Heinemann S: Cloned glutamate receptors. Annu Rev Neurosci 1994; 17:31-108
59. McGehee DS, Role LW: Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 1995; 57:521-546
60. Jackson MB: Dependence of acetylcholine receptor channel kinetics on agonist concentration in cultured mouse muscle fibers. J Physiol 1988; 397:555-583
61. Alkondon M, Reinhardt S, Lobron C, Hermsen B, Maelicke A, Albuquerque EX: Diversity of nicotinic acetylcholine receptors in rat hippocampal neurons, II: rundown and inward rectification of agonist-elicited whole-cell currents and identification of receptor subunits by in situ hybridization. J Pharmacol Exp Ther 1994; 271:494-506
62. 125I-neuronal bungarotoxin. J Neurosci 1991; 11:287-297
63. Sugaya K, Giacobini E, Chiappinelli VA: Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J Neurosci Res 1990; 27:349-359
64. 3H]nicotine binding in human cortex: relative abundance in subicular complex. J Chem Neuroanat 1992; 5:399-405
65. Rubboli F, Court JA, Sala C, Morris C, Chini B, Perry E, Clementi F: Distribution of nicotinic receptors in the human hippocampus and thalamus. Eur J Neurosci 1994; 6:1596-1604
66. Adem A, Nordberg A, Jossan SS, Sara V, Gillberg P: Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres. Neurosci Lett 1989; 101: 247-252
67. Cooper JR, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology, 7th ed. New York, Oxford University Press, 1996, pp 293-351
68. Grenhoff J, Aston-Jones G, Svensson TH: Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 1986; 128:351-358
69. Mereu G, Yoon KR Boi V, Gessa GL, Naes, Westfall TC: Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 1987; 141:395-399
70. Rasmussen K, Czachura JF: Nicotine withdrawal leads to increased firing rates of midbrain dopamine neurons. Neuroreport 1995; 7:329-332
71. Pauly JR, Marks MJ, Gross SD, Collins AC: An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. J Pharmacol Exp Ther 1991; 258: 1127-1136
72. Benwell MEM, Balfour DJK: Regional variation in the effects of nicotine on catecholamine overflow in rat brain. Eur J Pharmacol 1997; 325:13-20
73. Imperato A, Mulas A, Di Chiara G: Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 1986; 132:337-338
74. Andersson K, Fuxe K, Agnati LF: Effects of single injections of nicotine on the ascending dopamine pathways in the rat. Acta Physiol Scand 1981; 112:345-347
75. Clarke PBS, Fu DS, Jakubovic A, Fibiger HC: Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 1988; 246:701-708
76. Kirch DG, Gerhardt GA, Shelton RC, Freedman R, Wyatt RJ: Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain. Clin Neuropharmacol 1987; 10:376-383
77. Fowler JS, Volkow ND, Wang G-J, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schyler D, Wolf AP, Warner D, Zezulkova I, Cilento R: Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379:733-736
78. Pontieri FE, Tanda G, Orzi F, Di Chiara G: Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996; 382:255-257
79. Glassman AH: Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993; 150:546-553
80. Brioni JD, Kim DJB, Brodie MS, Decker MW, Arneric SP: ABT-418: discriminative stimulus properties and effect on ventral tegmental cell activity. Psychopharmacology (Berl) 1995; 119: 368-375
81. Mirza NR, Pei Q, Stolerman IP, Zetterstrom TSC: The nicotinic receptor agonist (-)-nicotine and isoarecolone differ in their effects on dopamine release in the nucleus accumbens. Eur J Pharmacol 1996; 295:207-210
82. Schulz DW, Kuchel GA, Zigmond RE: Decline in response to nicotine in aged rat striatum: correlation with a decrease in a subpopulation of nicotinic receptors. J Neurochem 1993; 61: 2225-2232
83. Liu C, Nordberg A, Zhang X: Differential coexpression of nicotinic acetylcholine receptor α4 and β2 subunit genes in various regions of rat brain. Neuroreport 1996; 7:1645-1649
84. Forsayeth JR, Kobrin E: Formation of oligomers containing the β3 and β4 subunits of the rat nicotinic receptor. J Neurosci 1997; 17:1531-1538
85. Le Novere N, Zoli M, Changeaux J-P: Neuronal nicotinic receptor α6 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur J Neurosci 1996; 8: 2428-2439
86. Nisell M, Nomikos GG, Hertel P, Panagis G, Svensson TH: Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse 1996; 22:369-381
87. Vezina P, Blanc G, Glowinski J, Tassin J: Nicotine and morphine differentially activate brain dopamine in prefrontocortical and subcortical terminal fields: effects of acute and repeated injections. J Pharmacol Exp Ther 1992; 261:484-490
88. Whiteaker P, Garcha HS, Wonnacott S, Stoleraman IP: Locomotor activation and dopamine release produced by nicotine and isoarecolone in rats. Br J Pharmacol 1995; 116:2097-2105
89. Sanderson EM, Drasdo AL, McCrea K, Wonnacott S: Upregulation of nicotinic receptors following continuous infusion of nicotine is brain-region-specific. Brain Res 1993; 617:349-352
90. Collins AC, Romm E, Wehner JM: Dissociation of the relationship between nicotine tolerance and upregulation of nicotinic receptors. Brain Res Bull 1990; 25:373-379
91. 3H]nicotine binding sites. Synapse 1995; 21: 281-288
92. Vidal C, Changeaux J-P: Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro. Neuroscience 1993; 56:22-32
93. Gray R, Rajan AS, Radcliffe KA, Yakehiro M, Dani JA: Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature 1996; 383:713-716
94. Braff DL, Saccuzzo DP: The time course of information-processing deficits in schizophrenia. Am J Psychiatry 1985; 142: 170-174
95. Freedman R, Adler LE, Baker N, Waldo M, Mizner G: Candidate for inherited neurobiological dysfunction in schizophrenia. Somat Cell Mol Genet 1987; 13:479-484
96. Freedman R, Hall M, Adler LE, Leonard S: Evidence in post-mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995; 38: 22-33
97. Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, Coon H, Griffith JM, Miller C, Myles-Worsley M, Nagamoto HT, Rollins Y, Stevens KE, Waldo M, Freedman R: Nicotinic receptor function in schizophrenia. Schizophr Bull 1996; 22:431-445
98. Bickford PC, Wear K: Fimbria-fornix lesions disrupt auditory sensory gating in the rat hippocampus. Brain Res 1995; 705: 235-240
99. Svensson TH, Grenhoff J, Engberg G: Effect of nicotine on dynamic function of brain catecholaminergic neurons, in The Biology of Nicotine Dependence. Edited by Bock G. New York, NY, Plenum, 1990, pp 169-185
100. Garcia-Munoz M, Patino P, Young SJ, Groves PM: Effects of nicotine on dopaminergic nigrostriatal axons requires stimulation of presynaptic glutamatergic receptors. J Pharmacol Ther 1996; 277:1685-1693